Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...
Google parent Alphabet named Eli Lilly Chief Financial Officer Anat Ashkenazi as its next CFO after nearly a yearlong search for a successor to Ruth Porat. Ashkenazi, who has been Eli Lilly’s ...
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on ...
INDIANAPOLIS: Drugmaker Eli Lilly and Co.'s second-quarter earnings fell 11 percent as it hiked marketing and research expenses to gear for a wave of patent expirations that will slash sales for ...
Core PCE Inflation Matches Estimates for AprilFri, 31 May 2024 12:48:04 GMT Euro Area Inflation Rises to 2.6%, Core CPI Jumps to 2.9%Fri, 31 May 2024 12:23:10 GMT German Retail Sales Slide by 1.2% ...
, opens new tab said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares. The ...